You need the Flash Player version 8.0.0.0 or higher and a JavaScript enabled browser to view this content

Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: PYC
News: Latest news
Web Site: Phylogica Limited
Other Articles:

RSS - Subscribe to the News Today on Proactive UK ▼

Saturday September 04, 06:00Serving up support at Babcock

Support services have been among the worst performing sectors over the past month as revenue fears from the government’s austerity measures weigh heavily on the sector.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Friday September 03, 11:40 Goldcorp snatches Andean Resources in $3.6bn deal, trumping Eldorado`s earlier bid

Both companies are vying for Andean`s Cerro Negro gold project, which is an advanced-stage, high-grade vein system, comprising 215 square kilometers. It currently has indicated resources of 2.54 million ounces of gold and 23.56 million ounces of silver, while inferred resources total 523,000 ounces of gold and 3.12 million ounces of silver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 10:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Phylogica Limited

Phylogica Limited

Phylogica (ASX: PYC) is a specialist drug discovery company, which screens the world's most structurally diverse library of biologics to identify leads for  large pharmaceutical companies.
Tuesday, March 02, 2010

Allowance of new European patent, major boost for Phylogica Ltd

company news image

Perth-based biopharmaceutical company Phylogica (ASX: PYC) has achieved a major patent milestone with the allowance of new European patent further broadening the company's ownership of the Phylomer peptide drug class.

Phylomer peptides belong to the fastest growing class of drugs, biologics (which include peptides, antibodies and other proteins). Phylomer libraries offer impressive hit rates with an increased quality as well as quantity of primary hits over random peptide libraries.

The patent allowance consolidates Phylogica’s dominance over the novel Phylomer peptide class.

Dr Paul Watt, CEO of Phylogica said, "all formalities following allowance have now been completed and the patent is expected to proceed to grant in the near future."

The recent allowance of Phylogica’s European Patent 06003767.8 (Publication No 1696038) has established even wider ownership of the Phylomer peptide class for the company.

This new patent establishes ownership of Phylomer libraries which can encode trillions of distinct compounds from a plethora of biodiverse sources.  The ownership extends beyond methods of constructing and screening Phylomer libraries, to include composition-of-matter on the libraries themselves.

The broadest granted independent claim covers the use of any combination of compact sequenced genomes from both Eukaryotes (like fungi, protozoa and higher organisms such us the Japanese puffer fish) or Prokaryotes (including bacteria or archaea),
regardless of their origin.

There is also no restriction to the size of genomic fragments required to construct Phylomer libraries.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Investors interested in Phylogica Limited recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.